{"organizations": [], "uuid": "4aa6360a2464e8af3913893d70b551af7a91acec", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/03/22/pr-newswire-artificial-pancreas-device-system-market-worth-390-point-4-million-by-2024-grand-view-research-inc.html", "country": "US", "domain_rank": 767, "title": "Artificial Pancreas Device System Market Worth $390.4 Million By 2024: Grand View Research, Inc.", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.874, "site_type": "news", "published": "2018-03-22T11:20:00.000+02:00", "replies_count": 0, "uuid": "4aa6360a2464e8af3913893d70b551af7a91acec"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/03/22/pr-newswire-artificial-pancreas-device-system-market-worth-390-point-4-million-by-2024-grand-view-research-inc.html", "ord_in_thread": 0, "title": "Artificial Pancreas Device System Market Worth $390.4 Million By 2024: Grand View Research, Inc.", "locations": [], "entities": {"persons": [{"name": "animas", "sentiment": "none"}], "locations": [{"name": "san francisco", "sentiment": "none"}, {"name": "animas", "sentiment": "none"}], "organizations": [{"name": "grand view research, inc", "sentiment": "neutral"}, {"name": "fda", "sentiment": "none"}, {"name": "tandem diabetes care", "sentiment": "none"}, {"name": "health canada license", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "SAN FRANCISCO, March 22, 2018 /PRNewswire/ --\nThe global artificial pancreas device system market is anticipated to reach USD 390.4 million by 2024, according to a new report by Grand View Research, Inc. Increasing prevalence of diabetes, intensive R&D efforts by industry players, and rising demand for automated systems for glycemic control are the key factors that are driving the market growth.\n(Logo: http://photos.prnewswire.com/prnh/20160524/371361LOGO )\nRegulatory bodies such as FDA are continuously approving new and innovative products which is increasing the reach of the companies in various market. For instance, in December 2016, OneTouch Vibe plus Insulin Pump by Animas received FDA approval and Health Canada License for the sale of the product. In January 2016, Animas received FDA approval for Animas Vibe Insulin Pump, the device to manage of diabetes in children and adolescents.\nSimilarly, in June 2016, Tandem Diabetes Care cleared its FDA approval for remote software update tool for insulin pump. Also, in September 2016, the company received FDA approval for their product t:slim G4 Insulin Pump giving the diabetes community a powerful new tool to help simplify therapy management Such factors are contributing to the growth of the market.\nAdditionally, the prevalence of diabetes is increasing in low and middle-income counties owing to the sedentary lifestyle, genetic modification, obesity, lack of physical activity, and unhealthy diet. According to the data published by the International Diabetes Federation(IDF), in 2015 there were about 415 million people suffering from diabetes globally. Also, based on the information provided by the American Diabetes Association, in 2012, about 29.1 million Americans suffered from diabetes out of which 90% were of type2 and 1.25 million suffered from type 1 diabetes. Furthermore, the increasing dependency of type 2 diabetes on insulin is expected to create opportunities for the artificial pancreas devices market.\nBrowse full research report with TOC on \" Artificial Pancreas Device System (APDS) Market Size, Share & Trends Analysis Report By Device Type (Threshold suspended device system, CTT System) And Segment Forecasts, 2013 - 2024 \" at: https://www.grandviewresearch.com/industry-analysis/artificial-pancreas-device-market\nFurther Key Findings From the Report Suggest:\nControl to Target (CTT) systems is anticipated to witness fastest growth during the forecast period as they are fully automated and require no intervention on the patient's part for the administration of insulin or for the monitoring of glucose levels. Asia Pacific artificial pancreas device system market is expected to grow with the highest CAGR over the forecast period owing to the lifestyle, genetic modification, urbanization and aging population. Major players of the market include, Medtronic Plc, Bigfoot Biomedical, Johnson & Johnson, Tandem Diabetes Care, Inc., Pancreum, Inc., TypeZero Technologies, LLC, and Beta Bionics.\nBrowse related reports by Grand View Research:\nHematology Analyzers and Reagents Market - Development of high throughput hematology analyzers are expected to be high impact rendering drivers of Hematology Analyzers and Reagents Market.\nCatheters Market - The global catheters market size was estimated at USD 26.38 billion in 2014 and is expected to grow at a CAGR of 9.7% from 2014 to 2020.\nTranscriptomics Technologies Market - The Global transcriptomics technologies market was valued at USD 2.2 billion in 2014.\nVentricular Assist Device Market - The Global Ventricular Assist Device (VAD) market was valued at USD 762.9 million in 2014 and is expected to witness positive growth over the forecast period.\nGrand View Research has segmented the global artificial pancreas device system market on the basis of device type and region:\nArtificial Pancreas Device System Device Type Outlook (Revenue, USD Million, 2013 - 2024) Threshold suspended device system CTR System CTT System Artificial Pancreas Device System Regional Outlook (Revenue, USD Million, 2013 - 2024) North America U.S. Canada Europe Germany UK Asia Pacific Japan China Latin America Brazil Mexico Middle East and Africa (MEA) South Africa\nRead Our Blog By Grand View Research: https://www.grandviewresearch.com/blogs/healthcare\nAbout Grand View Research\nGrand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.\nContact:\nSherry James\nCorporate Sales Specialist, USA\nGrand View Research, Inc\nPhone: +1-415-349-0058\nToll Free: 1-888-202-9519\nEmail: sales@grandviewresearch.com\nWeb: https://www.grandviewresearch.com\nSOURCE Grand View Research, Inc.", "external_links": ["http://photos.prnewswire.com/prnh/20160524/371361LOGO", "https://www.grandviewresearch.com/industry-analysis/artificial-pancreas-device-market?utm_source=pressrelease&utm_medium=referral&utm_campaign=PRN_Mar22_Artificial_Pancreas_Device_System_RD2&utm_content=Content", "https://www.grandviewresearch.com/industry-analysis/transcriptomics-technologies-market?utm_source=pressrelease&utm_medium=referral&utm_campaign=PRN_Mar22_Artificial_Pancreas_Device_System_RL3&utm_content=Content", "https://www.grandviewresearch.com/industry-analysis/artificial-pancreas-device-market?utm_source=pressrelease&utm_medium=referral&utm_campaign=PRN_Mar22_Artificial_Pancreas_Device_System_RD1&utm_content=Content", "https://www.grandviewresearch.com/industry-analysis/ventricular-assist-devices-market?utm_source=pressrelease&utm_medium=referral&utm_campaign=PRN_Mar22_Artificial_Pancreas_Device_System_RL4&utm_content=Content", "https://www.grandviewresearch.com/blogs/healthcare", "https://www.grandviewresearch.com/industry-analysis/hematology-analyzers-and-reagents-market?utm_source=pressrelease&utm_medium=referral&utm_campaign=PRN_Mar22_Artificial_Pancreas_Device_System_RL1&utm_content=Content", "https://www.grandviewresearch.com/industry-analysis/artificial-pancreas-device-market", "https://www.grandviewresearch.com/industry-analysis/catheters-market-analysis?utm_source=pressrelease&utm_medium=referral&utm_campaign=PRN_Mar22_Artificial_Pancreas_Device_System_RL2&utm_content=Content"], "published": "2018-03-22T11:20:00.000+02:00", "crawled": "2018-03-22T13:48:59.022+02:00", "highlightTitle": ""}